Trial · NCT01760187
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cmax for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Maximum observed plasma concentration for lomitapide |
| Primary | Tmax for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Time to maximum observed concentration for lomitapide |
| Primary | AUC0-t for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide |
| Primary | AUC0-∞ for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from zero to infinity for lomitapide |
| Primary | t1/2 for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Apparent terminal elimination half-life for lomitapide |
| Primary | Cmax for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27 | Maximum observed plasma concentration for lomitapide |
| Primary | Tmax for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27 | Time to maximum observed concentration for lomitapide |
| Primary | AUC0-t for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27 | Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide |
| Primary | t1/2 for Lomitapide | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27 | Apparent terminal elimination half-life for lomitapide |
| Secondary | Cmax for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Maximum observed plasma concentration for M1 metabolite of lomitapide |
| Secondary | Tmax for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Time to maximum observed concentration for M1 metabolite of lomitapide |
| Secondary | AUC0-t for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide |
| Secondary | AUC0-∞ for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from zero to infinity for M1 metabolite of lomitapide |
| Secondary | t1/2 for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Apparent terminal elimination half-life for M1 metabolite of lomitapide |
| Secondary | Cmax for M3 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Maximum observed plasma concentration for M3 metabolite of lomitapide |
| Secondary | Tmax for M3 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Time to maximum observed concentration for M3 metabolite of lomitapide |
| Secondary | AUC0-t for M3 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide |
| Secondary | AUC0-∞ for M3 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Area under the plasma concentration versus time curve from zero to infinity for M3 metabolite of lomitapide |
| Secondary | t1/2 for M3 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7 | Apparent terminal elimination half-life for M3 metabolite of lomitapide |
| Secondary | Cmax for M1 | 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27 | Maximum observed plasma concentration for M1 metabolite of lomitapide |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01760187/registered